For the year ending 2025-12-31, TGTX had -$100,702K decrease in cash & cash equivalents over the period. -$24,986K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 447,179 |
| Loss on extinguishment of debt | 0 |
| Noncash stock compensation expense | 64,670 |
| Depreciation and amortization | 59 |
| Amortization of discount on investment securities | 3,788 |
| Amortization of debt issuance costs | 1,216 |
| Amortization of leasehold interest | 185 |
| Deferred income taxes | -348,000 |
| Noncash change in lease liability and right of use asset | 1,748 |
| Change in fair value of equity investments | -298 |
| Change in fair value of notes payable | -27 |
| Change in inventory reserve | 6,171 |
| Increase in inventory | 33,452 |
| Increase in other current assets | 42,430 |
| Increase in accounts receivable | 176,443 |
| Increase in accounts payable and accrued expenses | 55,878 |
| Decrease in lease liabilities | -2,099 |
| (decrease) increase in other current liabilities | -2,381 |
| Increase in deferred revenue | 6,390 |
| Net cash used in operating activities | -24,772 |
| Proceeds from maturity of held-to-maturity securities | 237,500 |
| Investment in held-to-maturity securities | 222,237 |
| Investment in equity investments | 1,250 |
| Purchases of property, plant and equipment | 214 |
| Net cash provided by (used in) investing activities | 13,799 |
| Payment of loan payable | 0 |
| Issuance of common stock, net | 0 |
| Proceeds from exercise of options | 1,511 |
| Proceeds from debt financings | 0 |
| Financing costs paid | 0 |
| Purchase of treasury stock | 91,240 |
| Net cash (used in) provided by financing activities | -89,729 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -100,702 |
| Cash, cash equivalents and restricted cash at beginning of period | 181,192 |
| Cash, cash equivalents and restricted cash at end of period | 80,490 |
TG THERAPEUTICS, INC. (TGTX)
TG THERAPEUTICS, INC. (TGTX)